vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
CareTrust REIT, Inc. is the larger business by last-quarter revenue ($134.9M vs $123.8M, roughly 1.1× NATURES SUNSHINE PRODUCTS INC). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 3.3%, a 79.2% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 4.7%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 5.6%).
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
CTRE vs NATR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $134.9M | $123.8M |
| Net Profit | $111.3M | $4.1M |
| Gross Margin | — | 72.5% |
| Operating Margin | — | 4.3% |
| Net Margin | 82.5% | 3.3% |
| Revenue YoY | 55.1% | 4.7% |
| Net Profit YoY | 113.5% | 1379.4% |
| EPS (diluted) | $0.52 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.9M | $123.8M | ||
| Q3 25 | $132.4M | $128.3M | ||
| Q2 25 | $112.5M | $114.8M | ||
| Q1 25 | $96.6M | $113.2M | ||
| Q4 24 | $86.9M | $118.2M | ||
| Q3 24 | $77.4M | $114.6M | ||
| Q2 24 | $68.9M | $110.6M | ||
| Q1 24 | $63.1M | $111.0M |
| Q4 25 | $111.3M | $4.1M | ||
| Q3 25 | $74.9M | $5.3M | ||
| Q2 25 | $68.5M | $5.3M | ||
| Q1 25 | $65.8M | $4.7M | ||
| Q4 24 | $52.1M | $-321.0K | ||
| Q3 24 | $33.4M | $4.3M | ||
| Q2 24 | $10.8M | $1.3M | ||
| Q1 24 | $28.7M | $2.3M |
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 73.3% | ||
| Q2 25 | — | 71.7% | ||
| Q1 25 | — | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | — | 71.3% | ||
| Q2 24 | — | 71.4% | ||
| Q1 24 | — | 71.2% |
| Q4 25 | — | 4.3% | ||
| Q3 25 | 58.1% | 7.0% | ||
| Q2 25 | 61.3% | 3.7% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 43.0% | 4.6% | ||
| Q2 24 | 15.1% | 5.1% | ||
| Q1 24 | — | 4.2% |
| Q4 25 | 82.5% | 3.3% | ||
| Q3 25 | 56.6% | 4.2% | ||
| Q2 25 | 60.9% | 4.6% | ||
| Q1 25 | 68.1% | 4.2% | ||
| Q4 24 | 60.0% | -0.3% | ||
| Q3 24 | 43.2% | 3.8% | ||
| Q2 24 | 15.6% | 1.2% | ||
| Q1 24 | 45.6% | 2.1% |
| Q4 25 | $0.52 | $0.23 | ||
| Q3 25 | $0.35 | $0.30 | ||
| Q2 25 | $0.35 | $0.28 | ||
| Q1 25 | $0.35 | $0.25 | ||
| Q4 24 | $0.30 | $-0.02 | ||
| Q3 24 | $0.21 | $0.23 | ||
| Q2 24 | $0.07 | $0.07 | ||
| Q1 24 | $0.22 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $93.9M |
| Total DebtLower is stronger | $894.2M | — |
| Stockholders' EquityBook value | $4.0B | $161.6M |
| Total Assets | $5.1B | $261.1M |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.0M | $93.9M | ||
| Q3 25 | $712.5M | $95.6M | ||
| Q2 25 | $306.1M | $81.3M | ||
| Q1 25 | $26.5M | $86.5M | ||
| Q4 24 | $213.8M | $84.7M | ||
| Q3 24 | $377.1M | $78.7M | ||
| Q2 24 | $495.1M | $68.7M | ||
| Q1 24 | $451.2M | $77.8M |
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | $2.1M |
| Q4 25 | $4.0B | $161.6M | ||
| Q3 25 | $4.0B | $166.7M | ||
| Q2 25 | $3.3B | $163.7M | ||
| Q1 25 | $2.9B | $167.1M | ||
| Q4 24 | $2.9B | $161.0M | ||
| Q3 24 | $2.4B | $162.6M | ||
| Q2 24 | $1.9B | $156.4M | ||
| Q1 24 | $1.7B | $159.7M |
| Q4 25 | $5.1B | $261.1M | ||
| Q3 25 | $5.1B | $264.8M | ||
| Q2 25 | $4.7B | $254.9M | ||
| Q1 25 | $3.9B | $252.7M | ||
| Q4 24 | $3.4B | $240.9M | ||
| Q3 24 | $2.9B | $245.3M | ||
| Q2 24 | $2.7B | $235.8M | ||
| Q1 24 | $2.3B | $247.3M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 3.54× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.0M | $9.9M | ||
| Q3 25 | $100.9M | $18.5M | ||
| Q2 25 | $100.8M | $4.3M | ||
| Q1 25 | $71.4M | $2.6M | ||
| Q4 24 | $244.3M | $12.2M | ||
| Q3 24 | $67.2M | $9.6M | ||
| Q2 24 | $53.0M | $1.3M | ||
| Q1 24 | $48.8M | $2.2M |
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $-2.0M | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -1.4% |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 3.3% |
| Q4 25 | 3.54× | 2.41× | ||
| Q3 25 | 1.35× | 3.46× | ||
| Q2 25 | 1.47× | 0.81× | ||
| Q1 25 | 1.08× | 0.55× | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | 2.21× | ||
| Q2 24 | 4.92× | 0.97× | ||
| Q1 24 | 1.70× | 0.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTRE
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
